MRNA

Moderna, Inc.

$250.83

-6.75%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.

Source: Yahoo Finance
AI summary

Price & performance

1M+15.1%
3M+282.8%
YTD+618.5%
1Y+687.9%
52-week range—
Beta1.58
Full chart and returns against a benchmark

Q-Score

52/ 100

Quality against peers; 50 is the peer median.

Growth39
Risk45
Performance71
Valuation43
Profitability45
Leverage63
Sentiment27
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$1.9B-39.9%
Net income-$2.8B
Net margin-145.2%-35.1 pts
Historical fundamentals

Revenue exposure

38%of revenue from outside the US
United States62%
Rest of World36%
Europe3%
Largest customer15%
Regions, segments, customers and suppliers

Valuation

MRNAIndustryP/E—89.69P/S40.1911.88EV/EBITDA—67.10P/B14.846.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 6next report, before the open
EPS estimate$-1.30
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate